Home > Result Summaries: Compounds > Dutasteride > Result Summary for ARI40005

Result Summary for ARI40005

Result Summary
Protocol ID: ARI40005
Clinical Study ID: ARI40005
Official Title: See Detailed Description
Phase: phase 3
Study Indications or Diseases:
Generic Name: dutasteride
Trade/Product Name: Duagen,Zytefor,Avolve,Avodart,Avidart,Zyfetor
Approved Drug Label: http://www.gsk.com/products/prescription-medicines/index.htm
Results Summary: Click here to download result summary. Click here to download result summary.
Citations:
  • Roehrborn CG, Siami P, Barkin J, et al. The influence of baseline parameters on changes in International Prostate Symptom Score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009;55:461-71.
  • Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-21.
  • Chung B-H, Roehrborn CG, Siami P, et al. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis 2008.
  • Barkin J, Roehrborn CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign hyperplasia: 2-year data from the CombAT trial. BJU Int 2009.